Diabetes drug could boost standard arthritis treatment

NCT ID NCT04196868

Summary

This study is testing if adding the common diabetes medication metformin to the standard first-line arthritis drug methotrexate works better for controlling rheumatoid arthritis. It will involve 128 adults with active rheumatoid arthritis who are starting methotrexate treatment. The main goal is to see if the drug combination leads to lower disease activity after six months compared to methotrexate alone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, RHEUMATOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CH de Cahors - service de rhumatologie

    Cahors, France

  • CH de Libourne - service de rhumatologie

    Libourne, France

  • CH de Pau - service de rhumatologie

    Pau, France

  • CH de la Côte Basque - service de rhumatologie

    Bayonne, France

  • CH du Mans - service de rhumatologie

    Le Mans, France

  • CHD de Vendée - service de rhumatologie

    La Roche-sur-Yon, France

  • CHR Orléans la Source - service de rhumatologie

    Orléans, France

  • CHU de Bordeaux - service de rhumatologie

    Bordeaux, France

  • CHU de Brest - service de rhumatologie

    Brest, France

  • CHU de Montpellier - service de rhumatologie

    Montpellier, France

  • CHU de Toulouse - service de rhumatolgie

    Toulouse, France

  • Clinique de l'Infirmerie protestante de Lyon - service de rhumatologie

    Caluire-et-Cuire, France

Conditions

Explore the condition pages connected to this study.